CLINICAL INVESTIGATOR FINANCIAL DISCLOSURE CHECK-OFF BOX PROPOSED BY HOPKINS' BLAKE; FDA BACKS TAILORING REGULATIONS TO ISOLATE MOST "PERNICIOUS" CASES
Clinical investigators should disclose to FDA whether their financial involvement with a study sponsor exceeds a certain threshold but should not be required to make specific disclosures unless the agency so requests, Johns Hopkins Executive Vice Dean David Blake, PhD, suggested at an FDA Science Board meeting March 29.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth